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Dietary factors, microbial composition, and metabolism are intimately intertwined into a complex network
whose activities influence important intestinal functions. In a recent issue of Cell, Belcheva et al. (2014)
show that microbial-derived butyrate promotes proliferation of cancer-initiated intestinal epithelial cells,
suggesting that it can act as an oncometabolite.Colorectal cancer (CRC) is a complex
pathology integrating various host genetic
components, nutrition, inflammation, and
most recently, microbial composition
and associated activities. The latter has
gained attention for both cancer-promot-
ing as well as cancer-protecting effects.
The events dictating these microbial-
driven contradictory outcomes are not
clear, and intense investigations are
directed toward elucidating them. Since
the inception more than 5 years ago of
large-scale microbiome studies funded
by various worldwide agencies, the
scientific community has compiled an
impressive catalog of microbial commu-
nities living at several body sites during
various phases of life and under healthy
versus pathological conditions. With a
large majority of microorganisms residing
in the colon, it comes as no surprise that
this location has been under intense
scrutiny regarding the relationship be-
tween microbes and pathologies such as
necrotizing enterocolitis, inflammatory
bowel diseases (pediatric and adult),
recurrent Clostridium difficile infections,
irritable bowel syndrome, and CRC.
Although these studies have identified
differences in microbial compositions
between healthy individuals and those
afflicted by various disease states, knowl-
edge of the functional consequences of
these microbially unbalanced conditions
is more limited. For example, numerous
studies in patients with CRC have estab-
lished the presence of bacterial dysbiosis,
but the functional impact of the microbial
imbalances is still unknown.
Although efforts are still directed at
identifying microbes associated with
CRC, microbial functions have gainedtremendous attention as plausible causa-
tive factors of carcinogenesis. As a whole,
the microbiome has a prodigious meta-
bolic capacity, including the production
of diverse bioactive food components
and micronutrients such as essential
vitamins, and the fermentation of dietary
fibers and complex carbohydrates into
short-chain fatty acids (SCFAs) such as
acetate, propionate, and butyrate. Diet is
recognized as a key environmental factor
for cancer susceptibility, yet there is
limited insight regarding the interplay
between nutrition, microbes, and carcino-
genesis. In a recent issue of Cell,
Belcheva et al. demonstrate that either
antibiotic treatment or a low-carbohy-
drate diet attenuated intestinal polyp
formation (a precursor to CRC) in amouse
model by decreasing bacterial-derived
butyrate and diminishing epithelial cell
proliferation (Belcheva et al., 2014). The
study shows how diet andmicrobial activ-
ities contribute to cancer development
and highlights the need to decipher
the interplay between host genetics,
microbes, nutrition, and carcinogenesis.
To assess the impact of the microbiota
on carcinogenesis, Belcheva et al. (2014)
utilized an established model of human
adenomatous polyposis, the ApcMin/+
(multiple intestinal neoplasia) mice, that
were also deficient for the DNA mismatch
repair gene MutS homolog 2 (Msh2).
These ApcMin/+;Msh2/ mice showed
enhanced tumor number, particularly in
the colon, compared to ApcMin/+;Msh2+/
mice. When ApcMin/+;Msh2/ mice were
exposed to broad-spectrum antibiotic
treatment, they displayed a strong reduc-
tion in polyp formation in both the small
intestine and the colon at 6 weeks ofCell Host & Microbe 16age. Interestingly, 16S phylogenic anal-
ysis showed that the microbiota of
untreated ApcMin/+;Msh2/ mice and
ApcMin/+;Msh2+/ mice were similar, sug-
gesting that microbial activities, rather
than selective microbial species differ-
ences, were responsible for the enhanced
tumor burden. Host inflammatory envi-
ronment and/or epithelial DNA damage
have been identified as cancer-promoting
events, with some of these factors being
influenced by microorganisms (Schwabe
and Jobin, 2013). However, Belcheva
et al. did not observe any differences in
the distribution of immune cells between
ApcMin/+;Msh2/ mice and ApcMin/+;
Msh2+/ mice or modulation of cancer
development following genetic manipula-
tion of immune genes (Rag1/, caspase
1/). Similarly, somatic mutations or
gH2AX prevalence was not different
between genotypes or after antibiotic
treatment, suggesting that cancer promo-
tion in ApcMin/+;Msh2/ mice operates
through a different mechanism(s). Indeed,
expression of the proliferative markers
Ki-67 and b-catenin was enhanced, while
the differentiation marker p21 (Cip1/
WAF1) was reduced in ApcMin/+;Msh2/
mice.
The ability of the microbiota to bio-
transform various dietary components
into functional metabolites is likely inca-
pacitated when the ecosystem is disrup-
ted by antibiotic treatments or altered
by dietary manipulation. Belcheva et al.
(2014) tested the effect of a low-carbo-
hydrate diet on microbial community
composition and cancer development
in ApcMin/+;Msh2/ mice. While the low-
carbohydrate diet had no modulatory ef-
fect on microbial community composition, August 13, 2014 ª2014 Elsevier Inc. 143
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Figure 1. Microbiota-Derived Metabolism of Carbohydrates Promotes Polyp Frequency in
the Intestine
Butyrate-producing bacteria such as Clostridiaceae, Lachnospiraceae, and Ruminococcaceae bio-
transform carbohydrates into butyrate, which, in the context of cancer-initiated colonocytes such as those
observed in the epithelium of ApcMin/+;Msh2/mice, foster cellular proliferation and polyp formation. The
microbiota of ApcMin/+;Msh2/ mice exposed to low-carbohydrate diet or antibiotics is impaired in its
metabolic capacitiy and butyrate formation, thereby preventing cancer-initiated colonocyte proliferation
and cancer progression.
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reduced in both the small bowel (2-fold)
and the colon (6-fold) to a level similar
to antibiotic treatment. Abundance of
SCFA-producing bacteria Clostridiaceae,
Lachnospiraceae, and Ruminococcaceae
was reduced by antibiotic treatment or
a low-carbohydrate diet. SCFAs such
as acetate and butyrate have profound
effects on intestinal mucosal biology,
affecting both epithelial cell proliferation
and mucosal immune response. Interest-144 Cell Host & Microbe 16, August 13, 2014ingly, liquid chromatography-tandem
mass spectrometry (LC-MS/MS) analysis
showed that butyrate was significantly
diminished following either cocktail anti-
biotic treatment or a low-carbohydrate
diet, both being conditions that attenu-
ated polyp number in ApcMin/+;Msh2/
mice. To functionally determine the role
of butyrate in polyp formation, this partic-
ular SCFA was directly introduced either
by diet (tributyrin) or sodium butyrate
enemas, which mostly target the smallª2014 Elsevier Inc.intestine and colon, respectively. Strik-
ingly, these butyrate supplementation
strategies reversed polyp reduction af-
forded by antibiotic treatment in ApcMin/+;
Msh2/ mice and promoted epithelial
cell proliferation and tumor progression.
These findings suggest that microbial-
derived metabolism of carbohydrates
into SCFA such as butyrate may fuel
proliferation of cancer-initiated epithelial
cells, thereby promoting carcinogenesis
(Figure 1).
Interestingly, the findings of Belcheva
et al. suggest that butyrate functions
as an oncometabolite, a provocative
thought since numerous previous studies
have identified butyrate as a tumor-
suppressive metabolite (Bultman, 2014).
In addition, R5 human microbiome
sequencing projects have reported that
CRC cases have decreased abundance
of butyrate-producing bacteria compared
to healthy controls. Furthermore, when
butyrate is added to CRC cell lines, it
decreases cell proliferation while increas-
ing apoptosis and/or cell differentiation.
In fact, butyrate-induced expression of
p21 is responsible for the decreased
proliferation of HCT116 cells (Archer
et al., 1998). Yet, in the ApcMin/+;Msh2/
model, Belcheva et al. observed in-
creased butyrate levels in untreated
mice were correlated with decreased
expression of p21 (and increased cell pro-
liferation and polyp number) compared to
mice treated with antibiotics or provided
a low-carbohydrate diet. How does one
reconcile these seemingly disparate find-
ings? Butyrate is a pleiotropic molecule
that functions as an energy source, a his-
tone deacetylase (HDAC) inhibitor, and
an agonist of several G protein-coupled
receptors. It may thus have different
effects depending on the genetic back-
ground of the host. In this regard,ApcMin/+;
Msh2/ tumor initiation does not neces-
sarily involve dysregulated b-catenin
expression, which is different from the
more commonly studied ApcMin/+ and
azoxymethane (AOM) models (Kongka-
nuntn et al., 1999). Furthermore, MSH2
deficiency results in a mutator pheno-
type that magnifies the somatic genetic
background differences in the tumor
(Reitmair et al., 1997). In addition to ge-
netic background, age is a possible
confounding element because Belcheva
et al. analyzed their ApcMin/+;Msh2/
mice at 3–6 weeks of age, whereas most
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at adult stages (>8 weeks). It would be
important to confirm these findings using
different CRC models (e.g., Smad3/)
and also to determine whether the delete-
rious effect of butyrate ismediated through
Gprotein-coupled receptors (Jobin, 2014).
For example, reducing butyrate levels
through dietary manipulation (fiber) or mo-
lecular deletion (Gpr109a/) augmented
polyp formation in ApcMin/+ mice, a phe-
nomenon linked to decreased T regulatory
(Treg) cell differentiation (Singh et al.,
2014).
It is worth noting that this is not the
first instance of a ‘‘butyrate paradox.’’
Butyrate has long been known to have
differential effects on normal versus
cancerous colonocytes, and only recently
has this been addressed. Due to the
Warburg effect, butyrate is metabolized
by cancerous colonocytes to a lesser
extent and therefore accumulates as an
HDAC inhibitor (Donohoe et al., 2012).
Similarly, butyrate may have heteroge-
neous effects on tumorigenesis depend-
ing on host genetic background, the
presence of other bacterial metabolites
such as an omega-3 fatty acid (docosa-hexaenoic acid), which synergizes with
butyrate to induce colonocyte apoptosis
(Kolar et al., 2007), and whether it is
exerting a direct effect on the tumor (cell
autonomous) versus non-cell-autono-
mous effects such as regulating mucosal
immune cell activity as mentioned above.
Therefore, although the current study
contributes to our understanding of the
interplay between diet, microbes, and
CRC, the role of butyrate in cancer pro-
tection/promotion will still require further
investigation. Altering microbial activities
through dietary manipulation represents
an exciting means to harness the micro-
biome and influence health and disease
states. Whether dietary manipulation
could be used effectively to preserve
homeostatic functions afforded by micro-
biota while attenuating its potential
pathological effects is still an open
question, and more research would be
necessary before this strategy becomes
a reality.REFERENCES
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Helminth-induced immunomodulation is thought to influence the outcome of secondary infections. Osborne
et al. (2014) and Reese et al. (2014) demonstrate that helminth infection impacts viral infections by tilting the
immune system toward Th2/M2 immune regulatory responses that dampen Th1/M1 antiviral responses as
well as promote reactivation of latent herpesviruses.The mammalian intestine is home to
many pathogens, including commensal
bacteria, helminth parasites, and viruses.
Among these, helminths represent some
of the earliest recorded human infections
in history and remain a significant source
of infection today. Approximately 2.7
billionpeoplewho live in low-incomecoun-
tries in Africa, South America, and Asia arethought to have some type of helminth
infection (Hotez et al., 2007). In addition
to infectious complications, helminths are
also associated with human malignancy.
S. hematobium is a platyhelminth that is
associated with bladder cancer, particu-
larly in Egypt. Additionally,O. viverrini (liver
fluke) andC. sinesis are classifiedas group
1 carcinogens by the International Agencyfor Research on Cancer (IARC) (Bouvard
et al., 2009) and are causally associated
with cholangiocarcinoma, which is highly
prevalent throughout much of southeast
Asia and Egypt. The presumed mecha-
nisms include chronic inflammation and
hyperplasia of billary epithelium.
Helminth-induced immunomodulation
has long been thought to influence human, August 13, 2014 ª2014 Elsevier Inc. 145
